🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.

RecruitingNAAges 18 Years - 65 YearsAllTata Memorial Hospital
NCT02964858 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The purpose of this study is to compare standard dose radiation of 45 Gray(Gy) in 25 fractions in Non Hodgkin's Lymphoma- Diffuse Large B cell Lymphoma (NHL-DLBCL) to that of 36 Gy in 20 fractions. The role of radiation in NHL-DLBCL has been addressed in large cooperative trials showing improvement in overall survival and progression free survival with combined modality treatment. The doses of radiation used in these trials are heterogeneous ranging from 30-55 Gray(Gy). There is uncertainty about the optimal dose of radiation needed in aggressive lymphomas. A dose response phenomenon is known in Non- Hodgkin's Lymphoma. Late effects of higher dose radiation in the form of higher risk of stroke, myocardial infarction, thyroid abnormalities and secondary breast cancer are being increasingly identified. Hence it is essential to optimize the dose of radiotherapy for lower toxicity without c

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Histological Diagnosis of NHL- DLBCL. * Eligible for RT after R-CHOP. * ECOG 0-3. * 18 - 65 years. * Stage I-IV. * Patients should receive at least 4 cycles of R-CHOP chemotherapy. * Patients with all extranodal disease except the ones mentioned in the exclusion criteria. * Able to understand and willing to provide informed consent for participation in the trial. Exclusion Criteria: * HIV positive status. * Relapse or progression of disease during chemotherapy. * Prior history of chemotherapy * Prior history of radiotherapy. * Systemic lymphomas with CNS involvement. * Primary extranodal Testicular Lymphomas. * Primary extranodal central nervous system (CNS) Lymphomas. * Primary extranodal Stomach DLBCL * Primary extranodal Intestinal DLBCL * Patients \>3 extranodal sites
💊

What it tests

  • Standard Arm
  • Experimental Arm
📍

Where

1 site
Tata Memorial Center
Mumbai, India
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy